This Article Full Text Full Text (PDF) Data Supplement Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Naito, H. Articles by Zimmermann, W.-H. Search for Related Content PubMed PubMed Citation Articles by Naito, H. Articles by Zimmermann, W.-H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB LIOTHYRONINE Related Collections Structure Contractile function Cell biology/structural biology Growth factors/cytokines Transplantation CV surgery: transplantation, ventricular assistance, cardiomyopathy Other Research

(Circulation. 2006;114:I-72 – I-78.)
© 2006 American Heart Association, Inc.

Cardiac Transplantation and Surgery for Congestive Heart Failure

Optimizing Engineered Heart Tissue for Therapeutic Applications as Surrogate Heart Muscle

Hiroshi Naito, MD; Ivan Melnychenko, MD; Michael Didié, MD; Karin Schneiderbanger, MD; Pia Schubert, MD; Stephan Rosenkranz, MD; Thomas Eschenhagen, MD; Wolfram-Hubertus Zimmermann, MD

From the Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Germany.

Correspondence to Wolfram-Hubertus Zimmermann, Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Martinistr. 5, 20246 Hamburg, Germany. E-mail w.zimmermann{at}uke.uni-hamburg.de

Background— Cardiac tissue engineering aims at providing heart muscle for cardiac regeneration. Here, we hypothesized that engineered heart tissue (EHT) can be improved by using mixed heart cell populations, culture in defined serum-free and Matrigel-free conditions, and fusion of single-unit EHTs to multi-unit heart muscle surrogates.

Methods and Results— EHTs were constructed from native and cardiac myocyte enriched heart cell populations. The former demonstrated a superior contractile performance and developed vascular structures. Peptide growth factor-supplemented culture medium was developed to maintain contractile EHTs in a serum-free environment. Addition of triiodothyronine and insulin facilitated withdrawal of Matrigel from the EHT reconstitution mixture. Single-unit EHTs could be fused to form large multi-unit EHTs with variable geometries.

Conclusions— Simulating a native heart cell environment in EHTs leads to improved function and formation of primitive capillaries. The latter may constitute a preformed vascular bed in vitro and facilitate engraftment in vivo. Serum- and Matrigel-free culture conditions are expected to reduce immunogenicity of EHT. Fusion of single-unit EHT allows production of large heart muscle constructs that may eventually serve as optimized tissue grafts in cardiac regeneration in vivo.

Key Words: cardiomyocyte • myocardium • regeneration • tissue engineering • transplantation